- Trials with a EudraCT protocol (6,618)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6,618 result(s) found for: Disease Free Survival.
Displaying page 1 of 331.
EudraCT Number: 2005-003327-39 | Sponsor Protocol Number: KKSH-14 | Start Date*: 2006-04-21 |
Sponsor Name:Martin-Luther-University | ||
Full Title: Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II... | ||
Medical condition: oligometastatic breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001533-28 | Sponsor Protocol Number: AAML0531 | Start Date*: 2016-05-03 |
Sponsor Name:Children's Oncology Group | ||
Full Title: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults | ||
Medical condition: Acute myeloid leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-022902-41 | Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa... | |||||||||||||
Medical condition: Patients with operable HER2-positive primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) CZ (Completed) ES (Ongoing) FR (Ongoing) IE (Ongoing) SE (Ongoing) DK (Completed) SI (Ongoing) NL (Ongoing) BE (Ongoing) SK (Completed) AT (Trial now transitioned) IT (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002295-41 | Sponsor Protocol Number: PR2100 | Start Date*: 2009-01-29 |
Sponsor Name:The University of Birmingham | ||
Full Title: A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolo... | ||
Medical condition: Hormone refractory Prostate Cancer (HRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001939-38 | Sponsor Protocol Number: NIVINIHO | Start Date*: 2018-04-18 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions | |||||||||||||
Medical condition: patients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000082-41 | Sponsor Protocol Number: 2021-0486 | Start Date*: 2022-03-31 |
Sponsor Name:Fundación para la Investigación en Urología | ||
Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial | ||
Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002447-16 | Sponsor Protocol Number: 111482 | Start Date*: 2008-11-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma | |||||||||||||
Medical condition: Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as c... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004952-13 | Sponsor Protocol Number: DART | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) | |||||||||||||
Medical condition: - Prostate cancer patients with a biochemical recurrence following primary therapy - Hormone-sensitive - Up to 5 metastases on PSMA PET-CT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001360-39 | Sponsor Protocol Number: SU2C-SARC032 | Start Date*: 2019-06-24 | ||||||||||||||||
Sponsor Name:SARC | ||||||||||||||||||
Full Title: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity | ||||||||||||||||||
Medical condition: This trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005141-16 | Sponsor Protocol Number: NL75539.078.20 | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study. | |||||||||||||
Medical condition: non-metastatic resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003072-12 | Sponsor Protocol Number: 01082018 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:rigshospitalet | |||||||||||||||||||||||||||||||||
Full Title: Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in patients with cervical cancer | |||||||||||||||||||||||||||||||||
Medical condition: cervical cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021863-34 | Sponsor Protocol Number: RHMCAN0739 | Start Date*: 2011-02-10 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer | ||
Medical condition: Extensive stage small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000547-14 | Sponsor Protocol Number: BGOG-cx3 | Start Date*: 2017-08-30 | |||||||||||
Sponsor Name:BGOG-UZLeuven | |||||||||||||
Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer | |||||||||||||
Medical condition: recurrent cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011299-32 | Sponsor Protocol Number: 20060359 | Start Date*: 2010-08-06 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence | |||||||||||||
Medical condition: Early-stage non-metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) LV (Completed) FR (Completed) BE (Completed) SK (Completed) NL (Completed) IE (Prematurely Ended) DK (Completed) SI (Completed) GR (Completed) IT (Completed) BG (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000049-30 | Sponsor Protocol Number: RITE-2 | Start Date*: 2017-07-26 |
Sponsor Name:Medical Enterprises Europe B.V | ||
Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM... | ||
Medical condition: Non-Muscle-Invasive Bladder Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003051-11 | Sponsor Protocol Number: HEP102-DHELIVER | Start Date*: 2019-12-04 | |||||||||||
Sponsor Name:Promethera Therapeutics | |||||||||||||
Full Title: Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER | |||||||||||||
Medical condition: Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF), ACLF combines an acute deterioration of liver function in an individual with pre-existing chronic liver disease a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) DE (Trial now transitioned) LV (Ongoing) LT (Trial now transitioned) SK (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) PL (Trial now transitioned) PT (Completed) EE (Ongoing) AT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SI (Completed) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005067-33 | Sponsor Protocol Number: DBCG 07-REAL | Start Date*: 2009-02-09 |
Sponsor Name:DBCG | ||
Full Title: Randomized trial of endocrine therapy against locoregional therapy first. A DBCG trial in postmenopausal patients with operable hormone receptor positive tumors larger than 1 cm. | ||
Medical condition: Women age 60 or older with operable and hormone receptor positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005068-26 | Sponsor Protocol Number: H6Q-MC-JCAR(d) | Start Date*: 2005-06-17 |
Sponsor Name:Eli Lilly and Company limited | ||
Full Title: A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer | ||
Medical condition: metastatic colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003255-39 | Sponsor Protocol Number: MCL2004FI | Start Date*: 2005-02-08 |
Sponsor Name:The Finnish Lymphoma group | ||
Full Title: Treatment protocol for elderly patients with mantle cell lymphoma (MCL). A phase II study of the Finnish Lymphoma Group. | ||
Medical condition: Mantle cell lymphoma | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000167-16 | Sponsor Protocol Number: DIRECT-2016 | Start Date*: 2016-05-19 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trial | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.